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Abstract
Comparative binary outcome data are of fundamental interest in
statistics and are often pooled in meta-analyses. Here we examine the
simplest case where for each study there are two patient groups and a
binary event of interest, giving rise to a series of 2×2 tables. A variety
of measures of treatment effect are then available and are convention-
ally used in meta-analyses, such as the odds ratio, the risk ratio and
the risk difference. Here we propose a new type of measure of treat-
ment effect for this type of data that is very easily interpretable by lay
audiences. We give the rationale for the new measure and we present
three contrasting methods for computing its within-study variance so
that it can be used in conventional meta-analyses. We then develop
three alternative methods for random-effects meta-analysis that use
our measure and we apply our methodolgy to some real examples. We
∗This work was done while Dan was working at the MRC/BSU, Cambridge
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conclude that our new measure is a fully viable alternative to exist-
ing measures. It has the advantage that its interpretation is especially
simple and direct, so that its meaning can be more readily understood
by those with little or no formal statistical training. This may be es-
pecially valuable when presenting ‘plain language summaries’, such as
those used by Cochrane.
Keywords: Beta distribution; parallel trial; random-effect; Rel-
ative risk; Treatment effect
1 Introduction
In medicine, we often want to measure the effect of a treatment, usually a
drug or a medical intervention, and in epidemiology, we often wish to measure
the effect of exposure to some health hazard. Multiple studies that provide
relevant data are often available which may then be pooled in meta-analyses.
We consider the case of comparative binary outcome data, where for each
study there are two patient groups and a binary event of interest, such as
death. Interest then lies in determining which patient group is more likely
to experience the event. Most studies of this type are parallel studies, with
a control (or placebo) group and a treatment group. Occasionally, studies
are paired, where each patient acts as their own control. Here we focus on
parallel studies and the estimation of an appropriate treatment effect for the
resulting series of 2 × 2 tables. We will use random-effects meta-analyses
for this purpose, so that the possibility of between-study heterogeneity is
included in our modelling. If the strong assumption of homogeneity is made
then common-effect models may be used instead, which greatly simplifies the
statistical methods required.
Although the 2×2 table is a particularly simple and common data struc-
ture, the issues relating to the analysis of this type of data are subtle. In
particular, there are several issues that should be considered when deter-
mining an appropriate measure of treatment effect for this type of data.
For example, there is an important distinction between relative and abso-
lute measures (Deeks, 2002). The Cochrane handbook (Higgins and Green,
2011), its section 9.7, under the heading of sensitivity analyses, asks ‘for
dichotomous outcomes, should odds ratios, risk ratios or risk differences be
used?’. We therefore have three conventional measures of treatment effect for
performing meta-analyses involving comparative binary data but all of these
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measures can be difficult for lay audiences to interpret. For example, ac-
cording to Davies et al (1998), ‘odds ratios are hard to comprehend directly’,
and Grimes and Schulz (2008) state that ‘for most clinicians, odds ratios
will remain ... well, odd’. Risk ratios and differences are probably easier
to interpret but Schechtman (2002) explains that these measures also have
their disadvantages, where the problems stem from the fact that the same
risk difference or risk ratio might have very different implications depending
on the baseline risk. In order to make the risk difference more interpretable
its reciprocal, the number needed to treat (Nuovo, Melnikow and Chang,
2002), has been proposed; if the estimated risk difference indicates that the
treatment is not beneficial relative to the control then this measure is inter-
preted as the number needed to harm. The number needed to treat is a very
appealing and intuitive measure for non-statisticians to interpret but has
serious statistical difficulties (Hutton, 2002 and 2010). The poor statistical
properties of the number needed to treat are a consequence of the fact that
it is undefined under the null hypothesis where the probability of an event is
the same in both groups.
Our aim here is to develop a new measure of treatment effect for compar-
ative binary outcome data that, like the risk difference, takes values in the
interval [-1, 1], and is easily interpretable by non-statisticians. The proposed
measure will have a very simple and intuitively appealing interpretation,
along the lines of the number needed to treat. The effect will be zero under
the null. Minus one will indicate that no patients in the treatment group
experience the event (but some in the control do), and plus one will indicate
that all patients in the treatment group experience the event (but some in
the control group do not). The probability that patients in the treatment
group experience the event will be a monotonically increasing function of
the treatment effect, for a given probability in the control group. A related
idea to ours is the proposal of Mirzazadah, Malekinejad and Kahn (2015),
the ‘relative risk reduction of an undesirable outcome’. This is a simple
transformation of the relative risk, which our measure generalises. The dis-
advantages of our measure are that it will necessarily be unfamiliar, and so
appear strange to statisticians, and that it is not differentiable (but is con-
tinuous) at the null. However this is not a serious statistical difficulty in
practice. Our hope is that our ideas could be used to make meta-analyses
and systematic reviews, and indeed statistical analyses more generally, more
accessible to those with little or no formal statistical training. We return to
this issue in the discussion.
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The rest of the paper is set out as follows. In section 2 we summarise
existing measures, develop our new measure, describe three methods to com-
pute its variance and develop an accurate approximation to its distribution.
In section 3 we develop three random-effects models for meta-analysis that
use our new measure. The first of these models simply uses the conven-
tional random-effects model to describe the outcome data but the second
two models are novel and are motivated by the desire to make more accurate
inferences using our new measure. In section 4 we apply our new methods to
three real meta-analyses. We conclude in section 5 with a short discussion.
2 A new measure of treatment effect and its
properties
In this section we summarise the most popular existing measures of treatment
effect for analyzing 2 × 2 tables, develop our new measure and describe its
properties.
2.1 Existing measures
In this section we describe methods for a single 2×2 table and in section three
we will develop methods for the random-effects meta-analysis of multiple
tables. For comparative binary data, a variety of measures of treatment
effect θ are currently available. We will use θ to denote the treatment effect,
where the type of treatment effect that this refers to will be obvious from
the context, and ultimately we will use θ to denote our new measure.
Let p denote the probability of an event in the control group and let q
denote the probability of an event in the treatment group. All the measures
that follow are suitable functions of p and q. We will see below that our new
measure is another such function, but one where a simple causal explanation
can be used to communicate its meaning.
In the context of meta-analysis, Hartung, Knapp and Sinha (2008) also
give an account of many of the established measures that follow, to which
the reader is referred for more details.
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2.1.1 The odds ratio.
A very popular measure of the relative treatment effect is the odds ratio,
q/(1−q)
p/(1−p)
. This, and all the quantities that follow, are estimated by replacing
p and q with their estimates, pˆ and qˆ, which are the observed proportions
of patients that experience the event of interest in each group. Analyses are
usually performed on the log scale so that the log odds-ratio, ln{ q/(1−q)
p/(1−p)
} is
used in analysis. Inferences may then be back-transformed to the odds scale.
The log-odds ratio is undefined when p = 0, 1 or q = 0, 1 and halves or
some other quantity are usually added to all entries of the 2 × 2 table prior
to analysis to avoid this problem when there are zeros. This also applies
to the relative risk when either probability is zero. The odds ratio may
take any non-negative value, and the log odds ratio may take any value
(−∞,∞). As explained in the introduction, the odds ratio is not an easily
interpretable quantity for many consumers of statistical analyses, and its use
is usually motivated by its good statistical properties and connections with
other standard statistical methods, such as logistic regression.
The odds ratio is label-invariant and the log-odds ratio simply changes
sign when ‘good’ and ‘bad’ outcomes are switched; we use the shorthand
p → 1 − p, q → 1 − q to indicate this change. Similarly the log-odds ratio
switches sign when treatment and control groups are interchanged, for which
we use p↔ q. The invariance property of the log-odds ratio is another reason
why it is often preferred over some of the measures that follow.
2.1.2 The relative risk.
The relative risk of an event q/p, and the relative risk of not experiencing the
effect (1−q)/(1−p), are also commonly used relative measures of a treatment
effect. These measures are more easily interpretable than the odds ratio. As
with the odds ratio, analyses are usually performed on the log risk scale. The
relative risk of the event and not experiencing the event are not the same,
so the relative risk is not label-invariant when p → 1 − p, q → 1 − q, but is
invariant under p↔ q.
2.1.3 The risk difference.
The risk difference q− p is an absolute measure of treatment effect, that can
take values in the interval [-1,1]. It has the problem that if q = p + θ, for
some values of p, q will lie outside [0, 1] for θ ∈ [−1, 1]. In order to make
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this measure more interpretable, its reciprocal 1/(q− p), the number needed
to treat, has been proposed. However as explained in the introduction, the
number needed to treat has been criticised because of its poor statistical
properties which stem from the fact that it is undefined under the null where
p = q.
2.1.4 The arcsine difference.
The arcsine difference sin−1
√
q − sin−1√p is a risk difference with the vari-
ances of p and q stabilised using a variance stabilising transformation. This
measure has been proposed by Ru¨cker et al (2009), particularly in situations
where the event of interest is rare. The arcsine can take values in the interval
[−pi/2, pi/2].
2.1.5 Families of measures of treatment effects.
Jackson, Baker and Bowden (2013) propose a family of treatment effects of
the form T (q) − T (p) that includes many of the measures described above
and can be used in a sensitivity analysis. The transformation T used by
Jackson et al. was inspired by the one proposed by Aranda-Ordaz (1981)
that can also be used for this purpose.
2.2 New measure: The ‘GRRR’
One observation from section 2.1 is that a wide variety of measures of treat-
ment effect have been proposed and used in analysis. In particular, some of
these are routinely used in meta-analyses. Other than the number needed to
treat, which has poor statistical properties, all measures are, for one reason
or another, hard for lay audiences to interpret. In this section we develop
another measure, the ‘Generalised Relative Risk Reduction’, which gives rise
to the whimsical acronym ‘GRRR’. Our new measure has a very simple inter-
pretation, as is also the case for the number needed to treat, but the GRRR
has more acceptable statistical properties. The key concept is that as θ in-
creases from −1 one towards zero, an increasing (from zero) proportion of
those who experience the event under the placebo would also experience this
under treatment until θ = 0 when q = p. Also as θ subsequently increases
towards unity, an increasing proportion of those not experiencing the event
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under the placebo would experience this under the treatment. When θ = 1,
all patients in the treatment group experience the event.
We begin by considering the probability q as a function of p and the
new measure θ. We define q = q(p, θ) so as to ensure that θ represents a
meaningful and easily interpretable quantity. We will define our measure
differently for θ < 0 and θ > 0 whilst ensuring that θ is easily interpreted
in either case. We then put these definitions together to define our measure.
We require that θ = 0 is equivalent to q = p, and also that θ ∈ [−1, 1] acts
continuously on q, so that ∂q/∂θ > 0. Finally, we will ensure that θ = ±1
represents the greatest possible treatment effects.
2.2.1 The case where q > p.
If q > p, so that the event is at least as likely in the treatment group as in the
control (and is not certain in the control group) we define q = p + θ(1− p),
where 0 < θ < 1. This can be interpreted as meaning that, in addition
to the proportion who experienced the event in the control group (and who
would also have experienced the event if they were instead in the treatment
group), a further proportion θ of those who would not experience the event
in the control group would have experienced this event if they were in the
treatment group. For example, θ = 0.6 can be interpreted as meaning that
60% of patients who do not experience the event in the control group would
have experienced the event if they were in the treatment group. This may
be more easily understood as 1− q = (1− θ)(1− p), so that the proportion
1 − p not experiencing the event shrinks by a factor of 1 − θ. When θ = 1
we have that q = 1 > p, so that the event is certain in the treatment group
whilst not certain in the control group.
2.2.2 The case where q < p.
If q < p, so that the event is less likely in the treatment group (and is not
certain in the treatment group) we define q = (1 + θ)p where −1 < θ < 0.
This can be interpreted as meaning that, if θ is negative, a proportion 1 + θ
of those who would experience the event in the control group would also
experience the event if they were in the treatment group (and all those who
would not experience the event in the control group would also not experience
the event if they were in the treatment group). For example, θ = −0.6 can be
interpreted as meaning that 40% of patients who experience the event in the
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control group would also experience this event if they were in the treatment
group. When q = 0 and p > 0 we have θ = −1, so that θ = −1 indicates
that the event is impossible in the treatment group whilst being possible in
the control group.
2.2.3 The case where q = p.
If p = q then θ = 0 and we could take q = p+ θ(1− p), as in the case where
q > p, or q = p(1+ θ), as in the case where q < p. We take the former option
but this makes no material difference. Hence we arbitrarily use the definition
for the case where q > p to apply slightly more generally to q ≥ p.
2.2.4 Putting these three cases together and defining our new
measure.
The direct and easily interpretable nature of our new measure θ is now ap-
parent, because it may be interpreted as simply modifying the response of a
subset of the control group patients in order to produce the treatment group
probabilities. We have used the causal language that the ‘event would have
been different’ for some easily identified proportions of patients in the con-
trol group ‘if they had instead been in the treatment group’ when motivating
our measure. However we will see below that the measure θ is just another
suitable function of p and q that can be used to measure the treatment ef-
fect. Other explanations of why p and q take their values, and so result in a
particular value of θ, are of course also possible and more likely than the sim-
ple minded causal explanations that we have used to motivate the measure.
However our intention is to use this causal explanation for lay audiences to
explain one reason (of many) for the treatment effect observed. We are also
able to communicate the uncertainty in our estimates using this language, as
we demonstrate for some of our meta-analyses below.
Putting the three cases together, our proposed new treatment effect is
defined by the function
q =
{
(1 + θ)p if q < p
p+ θ(1− p) if q ≥ p. (1)
Succinctly, the probability of an event in the treatment group is
q = (1 + min(θ, 0))p+max(θ, 0)(1− p), (2)
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or q−p = min(θ, 0)p+max(θ, 0)(1−p). Writing min(θ, 0) = (θ−|θ|)/2, max(θ, 0) =
(θ + |θ|)/2, we have the alternative form
q − p = θ/2− |θ|(p− 1/2).
Solving (1) for θ gives rise to the definition of the GRRR of
θ =
{
(q/p)− 1 if q < p
1− (1− q)/(1− p) if q ≥ p. (3)
The nature of our generalised relative risk ratio is most evident from (3): if
q < p then it is the relative risk minus one, and if q ≥ p then it is one minus
the relative risk of not experiencing the event. Our measure is therefore a
type of generalised relative risk ratio, hence its name. Although we motivated
it without reference to risk ratios we can see now that it can be expressed
directly in terms of them. Therefore our measure is closely related to methods
that all statisticians will be familiar with, and is not such a radical departure
from conventional methods as it may at first appear. More succinctly we can
write
θ =
q − p
p+ (1− 2p)H(q − p) , (4)
where H is the Heaviside step function, such that H(x) = 1 if x > 0, else
zero if x < 0, and H(0) = 1/2; the case p = q has been correctly speci-
fied as θ = 0 for all p, q ∈ [0, 1]. Equation (4) appears to be an unusual
candidate for a measure of treatment effect but it is a convenient way per-
forming the calculation. We substitute the estimates pˆ, qˆ, which are just the
observed proportions of events in each treatment group, into (4) to produce
the estimated effect θˆ. Hence we can write
θˆ =
{
(qˆ/pˆ)− 1 if qˆ < pˆ
1− (1− qˆ)/(1− pˆ) if qˆ ≥ pˆ. (5)
and
θˆ =
qˆ − pˆ
pˆ+ (1− 2pˆ)H(qˆ − pˆ) , (6)
Although θ was motivated using risk ratios, the numerators in (4) and (6)
are the true and estimated risk differences, respectively. Hence these forms
shows how the proposed measure relates to this other well known measure
of treatment effect.
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Figure 1: Left: Equation (2) showing q plotted against θ for several values
of the control group probability p. Right: Equation (2) showing q plotted
against p for several values of the treatment effect θ.
A physical way to illustrate our measure, for those who think visually
rather than numerically, could be to take a vessel such as a bottle with a
long neck, the same length as the body, where in the neck the cross sectional
area p changes to 1 − p. The total capacity of the bottle is a unit volume.
The body of the bottle is sunk into the ground, with the bottom at −1 and
the top of the body at ground level, so that the top is at +1. Water is poured
into the bottle, and the height of the water level is θ. The volume of water
is q, so below ground level q = (1 + θ)p. At ground level, q = p and θ = 0,
and in the neck, q = p+ θ(1− p). The measure is shown in figure 1.
2.2.5 Properties of the proposed measure
The GRRR is ‘label-invariant’, under p → 1 − p, q → 1 − q. This type of
symmetry or label-invariance is thought desirable, because without it con-
clusions would depend on whether we looked at the proportion of patients
recovering, or the proportion not recovering. However, the widely used rel-
ative risk does not possess this property. Deeks (2002) however notes that
the ‘natural’ choice out of ‘good’ or ‘bad’ relative risk usually fits the data
better, so this lack of invariance is not a serious problem in practice.
Our measure is not label invariant with regard to switching the treatment
and control labels, when p ↔ q. This is a consequence of motivating the
measure by a consideration of simple causal implications of what would have
happened to patients in the control group if they had instead have been in
the treatment group: if we instead apply these causal implications to what
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would have happened to patients in the treatment group it is immediately
obvious that different inferences for θ will be made. In situations where one
group is the ‘placebo’ or ‘unexposed group, as is the case for all the examples
in this paper, then it is much more natural to ask the question of what would
have happened if patients in this group were treated or exposed, rather than
ask this question ‘the other way round’.
However in situations where two treatments ‘A’ and ‘B’ are compared
there is no such natural treatment ordering. To help the lay audience un-
derstand the relative merits of two such treatments, it may therefore be
useful to present two analyses, the first where ‘A’ is the control and ‘B’ is
the treatment, and then vice versa. The results can then be phrased by ex-
plaining the implications of the treatments if some patients in group A were
instead in group B, and then also if some patients were in group B instead
of group A. For showing that the treatments do not give identical results, a
label-invariant significance test could be performed.
The GRRR is not differentiable at θ = 0. This is a direct consequence of
the fact that it is defined differently for positive and negative values. This
is an undesirable property but we have not found it to be a serious issue in
practice. However this would be a problem for any further methods that, for
example, involved taking a Taylor series expansion that θ = 0. In any case,
this is a much less serious issue than the one presented by the GRRR’s main
competitor for an easily interpreted measure of treatment effect, the number
needed to treat, which is undefined when there is no treatment effect.
2.3 Computing the variance of the estimated treat-
ment effect
In order to make inferences using the proposed measure using a normal ap-
proximation (for example when using the conventional random-effects model
for meta-analysis, see our method 1 below) we need methods for calculating
the variance σ2 of θˆ. We use the notation in table 1, so that for example
we can write pˆ = n11/N1, qˆ = n12/N2. We propose three different ways to
compute σ2.
2.3.1 Analytical calculation of the variance.
For typical study sizes available, complete enumeration is simplest and most
accurate. Ru¨cker et al (2009) also consider this possibility for the arcsine
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event↓,group→ Control Treatment
Yes n11 n12
No n21 n22
Total N1 N2
Table 1: Notation for 2 × 2 tables; columns are the group, rows the event,
e.g. successful or unsuccessful.
difference, and refer to this as ‘analytical calculation of the variance’ and we
adopt their terminology here. Writing Pi to denote the binomial probability
of i control group responses, and Qj to denote the probability of j treatment
group responses, with Pi =
(
N1
i
)
pˆi(1 − pˆ)N1−i, Qj =
(
N2
j
)
qˆi(1 − qˆ)N2−j, we
have
E(θm) =
N1∑
i=0
N2∑
j=0
θmijPiQj , (7)
where θij is the value of θ corresponding to ˆˆp = i/N1, ˆˆq = j/N2. From these
calculations σ2 = E(θ2)− (E(θ))2.
For most sample sizes encountered in practice, it is currently perfectly
feasible to compute (7). The most efficient and robust way is to compute
probabilities recursively, starting at the mode and continuing both up and
down to very low probabilities. The correct scale factor for the probabilities
is found by requiring that they sum to unity. As is the case with the next
two methods, this approach provides only an approximate variance because
it ‘plugs in’ the point estimates pˆ and qˆ instead of using the true (unknown)
values p, q.
2.3.2 Monte Carlo calculation of the variance.
An alternative method is to use parametric bootstrapping, where we simulate
many binomial realizations from Pi and Qj, calculate θˆ and the variance of
these bootstrap replications gives the required variance. This method is at-
tractive in situations where N1 and/or N2 are large, so that the enumeration
required in the previous method is less feasible.
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2.3.3 An approximate formula for the variance.
The appendix give an approximate formula for the variance σ2. This is
based on the usual Taylor series expansion and normal approximation for
the logged relative risk. The resulting formula requires use of the standard
normal cumulative distribution but is very fast to compute and has been
found to work very well when 0.1 < p < 0.9, 0.1 < q < 0.9, and N1 >
100, N2 > 100. The analysis in the appendix treats the cases where q > p
and q < p separately, so that the non-differentiability at θ = 0 does not result
in any difficulties for the approximations used.
2.4 A split lognormal approximation for the distribu-
tion of θˆ
A normal approximation for θˆ can be used directly for making inferences
about θ and can be anticipated to be adequate in situations where such an
approximation for the risk difference is also reasonable (large samples, p and
q both not close to zero or one). Any of the three methods for computing the
variance of θˆ described above could be used in this approximation, so that
we approximate θˆ ∼ N(θ, σ2) where σ2 is treated as if fixed and known.
Those who might be reluctant to use a normal approximation for θˆ be-
cause it is also defined in terms of two estimated rate ratios in equation (5)
(for which analysis is usually performed on the log scale) would probably be
more willing to use normal approximations for sample proportions, and so
be willing to approximate the distribution of θˆ using ratios of two normal
distributions. Then, as Marsaglia (2006) points, out ‘approximations show
that many of the ratios of normal variates encountered in practice can them-
selves be taken as normally distributed’. Hence normal approximations for
θˆ are not necessarily immediately unacceptable.
However, we have found by simulating 2× 2 tables that the distribution
of θˆ often contains a skew tail. Hence normal approximations made directly
for θˆ are only very crude and a better approximation for the sampling distri-
bution of θˆ is desirable. Here we develop such an approximation using a split
lognormal distribution. This approximation will be used in our third model
for random-effects meta-analysis (model 3) below. Our split lognormal ap-
proximation simply uses conventional normal approximations for the log risk
ratios in (5) and then puts them together to approximate the distribution of
θˆ.
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Using the delta-method, we have approximately
ln(qˆ/pˆ) ∼ N(µ1, σ21) = N
(
ln(q/p),
1− q
qN2
+
1− p
pN1
)
, (8)
using the notation in Table 1, i.e. ln(qˆ/pˆ) is normally distributed with known
mean and variance. Similarly, take ln((1− qˆ)/(1− pˆ)) as
ln((1−qˆ)/(1−pˆ)) ∼ N(µ2, σ22) = N
(
ln((1− q)/(1− p)), q
(1− q)N2 +
p
(1− p)N1
)
.
(9)
These approximations work surprisingly well, and we use them both, so that
we approximate
X =
{
ln(1 + θˆ) ∼ N (µ1, σ21) if θˆ < 0
− ln(1− θˆ) ∼ N (−µ2, σ22) if θˆ ≥ 0.
(10)
Our definition of X in (10) ensures that X is increasing in θˆ, so that our
parameterisation makes computation as easy as possible. When using the
approximation for X , and so θˆ, in (10), we follow the usual convention of
taking the variances σ21 and σ
2
2 as known but we estimate them using pˆ and qˆ
in practice. To use (10) in order to specify the approximate distribution of θˆ
in terms of θ, all that is then required is to write µ1 and µ2 as functions of θ.
It is straightforward to write µ1 = ln(1 + θ) when θ < 0, and µ2 = ln(1− θ)
when θ ≥ 0. However it is not so straightforward to write µ1 and µ2 as
functions of θ when θ ≥ 0, and θ < 0, respectively, because then µ1 and µ2
are not directly specified by θ. In the appendix we explain how to overcome
this difficulty, so that the probability density function of θˆ can be written
in terms of θ when using the split normal approximation. We have found
that our split lognormal approximation is able to capture the skew tail of
the distribution of θˆ, and so is in general much more accurate than a crude
normal approximation.
We also explain how a variety of other inferences can be made for a
single 2 × 2 table using the split normal approximation in the appendix,
including the computation of confidence intervals and p-values. However for
the purposes of using the split normal approximation in meta-analysis (model
3, below) we require only the probability density function of θˆ as a function
of θ, so that likelihoods can be computed and the usual asymptotic theory
of maximum likelihood applied.
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3 Random-effects meta-analysis
We now present three different methods for performing random-effects meta-
analyses using our measure. These three contrasting methods are all 2-stage
methods because we require the computation of study specific data in the
first stage that are then pooled in the second stage. For method 1 (the
conventional random-effects model), in the first stage we compute the θˆi and
σ2i (where the σ
2
i may be computed using any of the above three approaches)
and we pool these outcome data in stage two in the usual way. For method
2 we use the same outcome data (the θˆi and σ
2
i ) but avoid using a normal
distribution, in order to avoid concerns about using this distribution for our
measure that is constrained to lie within [-1,1]. Finally for method 3 we use
the split-normal distribution to describe the within-study distributions and
we include non-normal random-effects. When using method 3 in the first
stage we compute the θˆi, and the variances σ
2
1i and σ
2
2i, required in the study
specific split lognormal within-study approximations from (10). In principle
1-stage meta-analyses (e.g. Simmonds and Higgins 2006), that avoid within-
study approximations and perform the analysis in a single stage, are possible
and we return to this possibility in the discussion.
3.1 Method one: The conventional random-effects method
This method is the simplest and most direct method: the study-specific
outcome data, θˆi and σ
2
i are computed and used directly as outcome data
in the random-effects model for meta-analysis θˆi ∼ N(θ, σ2i + τ 2). We refer
to it as the ‘direct method’ in the next section. Any of the above three
methods described above in section 2.3 for computing the σ2i could be used in
conjunction with this conventional approach. An advantage of this method
is that, having computed the θˆi and σ
2
i , standard meta-analysis software
packages can be used to perform the analysis. A variety of methods for
estimating τ 2 are available when using this standard approach (Veroniki et
al, 2016).
An advantage of using the new measure in this way is that there is no
need to add 1/2, or some other constant, to all counts to prevent infinities in
θˆi and σ
2
i . If both pi and qi are estimated as zero or unity, θˆi would be zero as
would its variance, and the study would be discarded; this is commonly done
with 2-stage methods with conventional measures such as the odds ratio.
A potential problem here is that assuming a normal distribution for θˆi
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is not especially appropriate, partly because θˆ ∈ [−1, 1], as discussed above.
However standard random-effects meta-analyses are often performed using
the risk difference, where this is also an issue but is not considered to be a
sufficient concern to avoid this approach. The next two methods address this
problem.
3.2 Method two: a random-effects model using the
beta distribution
The θˆi lie in the interval [-1,1]. In order to use the beta distribution to model
these estimates, we model the transformed outcome data ψˆi = (1 + θˆi)/2 so
that ψˆi ∈ [0, 1]. Specifically, the observed ψˆi is taken as a random variable
from the beta distribution with mean ψ = (1+θ)/2 and variance (σ2i +τ
2)/4,
where θˆi and σ
2
i are the same outcome data as in method one. Larger studies
contribute more weight to the analysis via their smaller σ2i , as in the more
conventional method above.
Thus the contribution to the likelihood from a study is
Li(θ, τ) = ψˆαi−1i (1− ψˆi)βi−1/B(αi, βi),
where B denotes the beta function. Here αi and βi are the parameters of
the beta distribution that models ψˆi, and so we must parameterise (αi, βi) in
terms of the mean ψ = (1 + θ)/2 and variance (σ2i + τ
2)/4 corresponding to
the ith study. Hence we take (αi, βi) to be the values that correctly provide
these two moments of ψˆi. This reparamerization of (αi, βi) to ψ = (1 + θ)/2
and (σ2i + τ
2)/4 is easily performed and is described in the appendix. The
likelihood function is then the product of the study specific Li(θ, τ) and
approximate inference is performed using the asymptotic theory of maximum
likelihood.
Note that here we must add halves, or some other quantity, when there are
zero counts or we will obtain zero probabilities under the beta distribution.
The transformation ψˆi = (1+ θˆi)/2 is very simple so that inferences are easily
back-transformed to the original scale.
3.3 Method three: a random-effects method using the
split-lognormal approximation
Here the split lognormal approximation, from equations (8), (9) and (10) is
used to model the within-study distributions. As explained in section 2.4,
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we can specify the approximation in terms of the GRRR. We can therefore
apply this approximation to each study, and in terms of its study specific
true underlying effect θi. If we assume a common-effect model (τ
2 = 0), so
that θi = θ for all i, inference is easily formed using maximum likelihood as
for the previous model where the likelihood function is the product of the
Li(θi) = Li(θ). Larger studies contribute more weight to the analysis via
their smaller σ21i and σ
2
2i used in their study specific split lognormal approx-
imation (equations 8, 9 and 10).
To include a random effect, and so fit a random-effects model, we take
ψi = (1 + θi)/2 to have a beta distribution, with mean ψ = (1 + θ)/2 and
variance τ 2/4. Written in terms of ψi, the within-study likelihood Li(θi) is
Li(2ψi + 1). This within-study likelihood is then integrated over the distri-
bution of ψi in order to integrate out the random-effects in the usual way, so
that
L(θ, τ) =
∫ 1
0
Li(2ψi − 1)ψα−1i (1− ψi)β−1 dψi
B(α, β)
.
where this integration is performed numerically. As in method 2, approxi-
mate inference is performed using the asymptotic theory of maximum like-
lihood. Here α and β are chosen so that E(ψi) = ψ = (1 + θ)/2 and
var(ψi) = τ
2/4. This reparameterisation is similar to the one used in method
2 and is also described in the appendix.
This is a similar approach to modelling the random effect as in the pre-
vious method. A conceptual difference is that in method 2 we used a beta
distribution to model the ψˆi but here we instead use this distribution to
model the true underlying ψi; we assume that the ψi follow a common distri-
bution so that the same α and β are used for all studies when computing the
likelihood. In this sense method 3 is computationally simpler, but it requires
a separate numerical integration for every study when computing the likeli-
hood. Hence method 3 is the most computationally expensive of the three
methods that we propose, but uses the most realistic model.
4 Application to meta-analysis datasets
In this section we will use 3 real examples to illustrate the use of our mea-
sure in practice. The first example involves thirteen randomized control trials
from 1948 to 1976 on the prevention of tuberculosis using the BCG (Bacillus
Calmette-Gue´rin) vaccine, with data given in Hartung, Knapp and Sinha
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(2008), but taken originally from Colditz et al (1994). The event of interest
is contracting tuberculosis. The second example involves 22 trials of strep-
tokinase following mycocardial infarction, given in Egger, Altman and Smith
(2001). Briefly, from 1959, 21 trials were carried out to see whether strep-
tokinase could reduce 6-month mortality from infarction; this was feasible
because streptokinase can dissolve blood clots. Here the event of interest is
death. The third example one of the eleven randomised control trials of lam-
otrigine (Ramaratnam, Panabianco and Marson, 2016), from 1989 to 2007,
as an adjunctive therapy for the treatment of drug-resistant partial epilepsy.
The outcome is a 50% or more reduction in seizure frequency.
Table 2 shows the results from using all three methods described in section
3 on our main three examples using maximum likelihood estimation and the
asymptotic theory of maximum likelihood to make inferences. The within-
study variance was computed exactly (by enumeration) for methods 1 and
2. Table 3 shows the results using the two stage method described in section
3.1, instead using the the Dersimonian and Laird (1986) method. In Table 3
the quoted τˆ is the square root of the corresponding DerSimonian and Laird
estimate τˆ 2. It can be seen that the results using the more conventional
DerSimonian and Laird method are very similar to those using our ‘direct’
method.
Analysis method Dataset θˆ s.e. τˆ s.e.
2-stage Direct (sec 3.1) TB -.496 .088 .292 .066
2-stage Beta (sec 3.2) TB -.489 .083 .270 .061
2-stage Lognormal (sec 3.3) TB -.505 .075 .239 .053
2-stage Direct (sec 3.1) Strept -.170 .045 .149 .043
2-stage Beta (sec 3.2) Strept -.174 .045 .152 .041
2-stage Lognormal (sec 3.3) Strept -.200 .023 0 0
2-stage Direct (sec 3.1) Lamot .201 .036 .078 .031
2-stage Beta (sec 3.2) Lamot .200 .036 .031 .060
2-stage Lognormal (sec 3.3) Lamot .132 .030 .049 .046
Table 2: Results for the new measure applied to three examples, using all
three methods.
The outcomes are harmful (death and contracting tuberculosis) in our
first two examples and beneficial (reduction in seizure frequency) in our third
example. Hence θ < 0 indicates treatment benefit in the first two examples
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Analysis method Dataset θˆ s.e. τˆ I2%
2-stage Direct (sec 3.1) TB -.493 .102 .345 97.6
2-stage Direct (sec 3.1) Strept -.168 .041 .133 63.0
2-stage Direct (sec 3.1) Lamot .202 .033 0 0
Table 3: Results for the new measure applied to parallel studies, using the
Dersimonian and Laird method and assuming a normal distribution for θˆ.
and θ > 0 indicates treatment benefit in the third example. Using the results
in Table 2, and normal approximations for the maximum likelihood estimates,
we infer that the treatment is beneficial in all three examples. Our use of
the GRRR then allows us to communicate these findings to a lay audience
in a very simple and direct way. For example, let us take θˆ = −0.5 from
Table 2 for our first example (TB). We are then able to tell a lay audience
that one way to explain the extent of the treatment efficacy is to say that
we estimate that 50% (i.e. half) of the population who do not take the
vaccine and contract TB would also contract TB if they instead took the
vaccine (where we assume that all those who would not contract TB without
taking the vaccine also would not contract this if they took the vaccine). In
other words, we estimate that around half the population who do not take
the vaccine and contract TB would instead avoid contracting this if they
had taken the vaccine. Statements such as these nicely convey the notion
that the vaccine has real benefit (but is not perfect) in a simple way, whilst
being statistically principled. We can also quantify the uncertainty in this
statement. From a 95% confidence interval for θ this, the 50% that we quoted
could in fact be between around 30%-70%.
As another illustration, let us take θˆ = 0.2 from Table 2 for our third
example. We are then able to tell a lay audience that one way to explain
the extent of the treatment efficacy is to say that, in addition to those who
experience notable seizure frequency in the reduction without the lamotrigine
(and would also experience this if they took this treatment), a further 20% of
those who do not experience notable seizure frequency without lamotrigine
would instead experience this if they took the treatment. However there
is uncertainty in this estimate and (from a 95% confidence interval for θ)
this percentage could be between around 10%-30%. Again, these statements
clearly convey the potential benefit of taking the treatment in an especially
direct and transparent manner.
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A final point is that analysts may be reluctant to use our proposed mea-
sure in analysis because it is unconventional, but may wish to convert results
using other measures to it, so that explanations such as these can be given.
This conversion can be performed upon adopting a representative baseline
risk p for the control group and we give full details of the calculation required
in the appendix for converting the odds ratio in this way. We return to this
issue in the discussion.
5 Discussion
A new treatment effect measure (generalized relative risk reduction, or ‘GRRR’),
based on relative risk, has been introduced. The new measure gives a treat-
ment effect on a scale from minus one to plus one, with zero indicating no
treatment effect. There is a clear causal interpretation that accompanies the
new measure and that can be used to communicate the results to those with
little or no formal statistical training. Those who are faced with explain-
ing the findings from meta-analyses, and statistical analyses more generally,
to the general public are likely to find our new measure especially useful.
This may include journalists and politicians as well as clinicians. Health
economists may also find this measure useful, as costs of using or not using a
new intervention are straightforward to calculate. We suggest that interpre-
tations using our measure could be included in ‘plain language summaries’
that accompany Cochrane reviews and other information sources that are
intended for a wide audience. For the ‘take-home’ messages from statistical
analyses to be fully appreciated by the general public we require methods
such as those that we present here. We hope that, at the very least, our
methods will provide further ideas for communicating statistical findings in
a simple and direct, and yet still statistically principled, manner that is
widely accessible.
We have developed three methods for performing 2-stage random-effects
meta-analysis that use our new measure. We therefore have proof of concept
that it may be used in conjunction with quite sophisticated statistical mod-
els. Future work could focus on other types of models where binary outcome
data are modelled, such as logistic regressions and generalised linear mixed
models. For example, regression modelling could be carried out by allowing
ψ = (1 + θ)/2 ∈ [0, 1] to be a logistic function of covariates. These possibili-
ties for more complex modelling include 1-stage methods for random-effects
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meta-analysis and the authors have developed two further methods of this
type. These 1-stage methods have been found to produce similar results to
the 2-stage methods presented here and may form the subject of future work.
We have also performed a small scale empirical investigation to determine if
the proposed measure results in better model fits than the more conventional
(log) odds ratio. Further investigation is needed but our preliminary inves-
tigation suggests that models using our measure describe real meta-analysis
datasets just as well as more conventional measures of treatment effect.
Rather than motivate our new measure as providing better fitting mod-
els to data, we have proposed it primarily so that the resulting statistical
inferences can be more easily communicated to general audiences. We sug-
gest therefore that it is particularly suited to providing results that could be
communicated in plain language summaries such as those used by Cochrane.
It is most straightforward to report results using our measure after actually
using our measure as the outcome in analysis, but we suspect that many ana-
lysts would object to this idea unless our measure becomes more widely used
and accepted. We would encourage analysts who might be uncomfortable in
using our new measure in analysis to consider converting their results using a
measure of their choice to ours, so that conclusions using our measure can be
reported despite the fact that an alternative measure was used in analysis.
A classical (frequentist) approach to statistical inference has been adopted
here but the likelihood-based methods can also be used for Bayesian infer-
ence. Prior distributions for all parameters would then be needed. The main
difficulty is determining a suitable prior distribution for θ, and the beta dis-
tribution for ψ is an obvious candidate. It can be used when there is a lot of
prior information, and also includes as special cases the uniform and Jeffreys
priors. Markov chain Monte Carlo (MCMC) would probably be used to per-
form analyses because the resulting posterior distributions are unlikely to be
analytically tractable.
The only other candidate measure of treatment effect for 2 × 2 tables
that is so easily interpretable is the number needed to treat. However this
measure has unacceptable statistical properties. We suggest that the GRRR
is suitable as a replacement for this measure as it is both easily interpretable
and has acceptable statistical properties. The GRRR has however two unde-
sirable properties: it is not invariant when the treatment and control groups
are interchanged, as we have explained, and furthermore θ is not differen-
tiable when θ = 0. This latter property has not caused us any problems
here but this could result in difficulties for the unwary. At the very least,
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our proposed measure has much better properties than the number needed
to treat, which we regard as its main contender for an easily interpreted
and intuitively appealing measure of treatment effect for comparative binary
outcome data.
To summarise, we hope that meta-analysts, and indeed the the statistics
community more generally, will be convinced by the case for our new measure
of treatment effect, and that they will find it to be a useful new way to
measure and communicate the results from comparative trials that involve a
binary event of interest. We also hope that our work will serve to stimulate
debate about the best way to communicate statistical conclusions to those
with little or no formal statistical training.
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6 Appendix: detailed formulae
6.1 The split-lognormal distribution
In section 2.4 of the main paper we explain that it is possible to write the
probability density function (pdf) of θˆ in terms of θ. In this section of the
appendix we give full details about how this is done.
To derive an approximation for the sampling distribution of θˆ, using the
delta method and assuming normality of the logged risk ratio, we take ln(qˆ/pˆ)
as obeying (8) and (1− qˆ)/(1− pˆ) as obeying (9), where these equations are
in the main paper. Then qˆ/pˆ follows a lognormal distribution. Similarly,
(1 − qˆ)/(1 − pˆ) follows a lognormal distribution, and θˆ is as defined in (10)
via X . From this approximation for X , and hence θˆ, the pdf and distribution
function of θˆ can be obtained. Hence p-values, confidence intervals, and the
moments of this distribution may also be computed.
6.2 The probability density function and the cumula-
tive distribution function of θˆ
We can identify four cases from equation (10) and we evaluate the pdf for
each case. Then the pdf is then defined for all cases. These four cases arise
because θˆ can take either sign (we use normal approximations and so the
probability that θˆ = 0 is zero), and θ can be of the same sign as θˆ or not.
To see why we consider these four cases separately, consider the first line in
the right hand side of (10), which applies to θˆ < 0. If θ < 0, so that θˆ and
θ are both negative, then it is straightforward to write µ1 = ln(1 + θ) and a
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normal approximation for X , and hence θˆ, is immediate for the combination
of θˆ < 0 and θ < 0. However if θˆ < 0 and θ ≥ 0 then we no longer have
µ1 = ln(1 + θ) and the parameterisation of the normal approximation is not
quite so immediate. Following a similar argument for the second line in the
right hand side of (10), we can see that the difficulties occur when θˆ and θ
are not of the same sign, and so we adopt a ‘divide and conquer’ approach
of considering each case separately.
When θˆ < 0, θ < 0, we have the approximation ln(1 + θˆ) ∼ N [µ1 =
ln(q/p) = ln(1 + θ), σ21], and so the pdf
f(θˆ) =
exp{−(ln(1 + θˆ)− ln(1 + θ))2/2σ21}√
2piσ21(1 + θˆ)
.
The corresponding distribution function is
Φ{(ln(1 + θˆ)− ln(1 + θ))/σ1}, (11)
where Φ(·) is the standard normal distribution function. Here we have used
the fact that µ1 = ln(q/p) = ln(1 + θ). However, when θ ≥ 0, µ1 is not
specified by θ. This is because θ = 1 − (1 − q)/(1 − p) when θ ≥ 0 from
which q/p cannot be determined. However, a substitute value can be found
by requiring that the total probability is unity. We therefore use the fact
that
Prob(qˆ/pˆ > 1) = Φ(µ1/σ1) = Prob((1− qˆ)/(1− pˆ)) < 1 = Φ(−µ2/σ2)
to obtain the useful result
µ1/σ1 = −µ2/σ2 (12)
from which, because µ1 = ln(q/p), the approximate mean of ln(1 + θˆ) for
θˆ < 0 can be found from µ2 = ln((1 − q)/(1 − p)), which is also equal to
ln(1− θ) when θ ≥ 0. Using (12), when θˆ < 0, θ ≥ 0
f(θˆ) =
exp{−(ln(1 + θˆ) + (σ1/σ2) ln(1− θ))2/2σ21}√
2piσ21(1 + θˆ)
.
The corresponding distribution function is
Φ{ln(1 + θˆ)/σ1 + ln(1− θ)/σ2}.
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Similarly, when θˆ ≥ 0, we have for θ ≥ 0 that
f(θˆ) =
exp{−(ln(1− θˆ)− ln(1− θ))2/2σ22}√
2piσ22(1− θˆ)
.
The corresponding distribution function is
Φ{(− ln(1− θˆ) + ln(1− θ))/σ2}, (13)
where the minus sign arises because ln(1 − θˆ) is a decreasing function of θˆ.
Finally for θˆ ≥ 0, θ < 0
f(θˆ) =
exp{−(ln(1− θˆ) + (σ2/σ1) ln(1 + θ))2/2σ22}√
2piσ22(1− θˆ)
.
The corresponding distribution function is
Φ{− ln(1− θˆ)/σ2 − ln(1 + θ)/σ1}.
6.2.1 P-values and confidence intervals
At the end of section 2.4 of the main paper we explain that other inferences
can be made for a single 2× 2 table. In this section of the appendix we give
full details of this.
First, p-values are given when θ = 0 so that µ1 = µ2 = 0. The 1-
sided p-value for obtaining θˆ at least as large as observed when θˆ ≥ 0 is
Φ(ln(1 − θˆ)/σ2), using (13) and the identity 1 − Φ(x) = Φ(−x). The 1-
sided p-value for obtaining θˆ at least as negative as observed when θˆ < 0 is
Φ(ln(1+ θˆ)/σ1) from (11). From (11) and (13) we obtain the formula for the
corresponding 2-sided p-values, i.e. for θˆ to exceed the observed |θˆ| in either
direction. This is
p = Φ(ln(1− |θˆ|)/σ1) + Φ(ln(1− |θˆ|)/σ2)
from which we can see that the 2-sided p-value is 1 if θˆ is exactly zero (this
is impossible using normal approximations but could arise in real data.)
Confidence intervals for θ can be computed by equating quantiles of the
pdf to the required values. When θˆ ≥ 0, from (13) and the corresponding
pdf we obtain the size α limits for ln(1− θ) as ln(1− θˆ)±σ2zα/2, where zα is
the 100α percentile of the normal distribution. From this the limits for θ are
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θ = 1 − (1 − θˆ) exp(±σ2zα/2). However this calculation assumes that θˆ ≥ 0
and θ ≥ 0 but it may happen that lower limit is negative so that we have
θˆ ≥ 0 and θ < 0 at the lower end of the confidence interval. In this case, the
lower limit must be recomputed as
θ = (1− θˆ)−σ1/σ2 exp(−σ1zα/2)− 1.
This follows by using (12) to deal with the issue that the signs of θˆ and θ are
not the same and proceeding in a similar way as when deriving the pdf and
cumulative distribution function.
Similarly, when θˆ < 0, the confidence interval is θ = (1+θˆ) exp(±σ1zα/2)−
1, unless the upper limit is positive, in which case it should be recomputed
as θ = 1− (1 + θˆ)−σ2/σ1 exp(σ2zα/2).
6.3 The variance of θˆ
In order to use standard methods for meta-analysis we require within-study
variances. In section 2.3.3. of the main paper we discuss an approximate
formula for this. In this section of the appendix we derive this formula.
A large-sample approximation for the variance of θˆ has been developed,
and works very well when 0.1 < p < 0.9, 0.1 < q < 0.9, and N1 > 100, N2 >
100. Because of the tractability of the lognormal distribution, one can cal-
culate An = EL{(qˆ/pˆ)n}, where the integral for the expectation is truncated
at qˆ/pˆ = 1, so that the expectation is calculated over the range where qˆ < pˆ,
i.e.
An =
1√
2piσ21
∫ 1
0
xn−1 exp(−(ln(x)− µ1)2/2σ21) dx.
This integral can be evaluated analytically by changing variable to y = ln(x),
so that the integration is now performed over (−∞, 0), and completing the
square in the exponent. Similarly Bn = ER{((1 − qˆ)/(1 − pˆ))n} can be
calculated as
Bn =
1√
2piσ22
∫ 1
0
xn−1 exp(−(ln(x)− µ2)2/2σ22) dx
where the integral for the expectation is truncated at (1 − qˆ)/(1 − pˆ) = 1,
so that the expectation is calculated over the range where 1− qˆ ≤ 1− pˆ, or
qˆ ≥ pˆ. Evaluating the integrals analytically gives
An = (q/p)
n exp(n2σ21/2)Φ(−µ1/σ1 − nσ1),
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Bn = ((1− q)/(1− p))n exp(n2σ22/2)Φ(−µ2/σ2 − nσ2).
Hence we have one approximation for qˆ < pˆ (the ‘left’ side of the distribution),
and a different approximation for qˆ ≥ pˆ (the right side). From the definition
of θˆ we then have
E(θˆ) = EL(qˆ/pˆ− 1) + ER(1− (1− qˆ)/(1− pˆ)) = A1 − A0 +B0 − B1,
E(θˆ2) = A2 − 2A1 + A0 +B2 − 2B1 +B0,
from which the variance of θˆ can be computed as E(θˆ2) − E(θˆ)2, on replac-
ing p, q in the formula by pˆ, qˆ respectively. Note that we have evaluated the
expectation of θˆ from its definition, where we have evaluated this expecta-
tion by integrating over the two areas of the sample space separately. This
approximation to σ2 is surprisingly accurate. It requires the computation of
the normal distribution function 6 times.
7 Reparameterising the beta distribution
As explained in sections 3.2 and 3.3, to use methods 2 and 3 we need to
specify the mean ψ and variance σ2 of a beta distribution, and then compute
the usual beta function parameters α, β within the section of computer code
that computes the log-likelihood function. We give the details here. For
method 2 this mean is ψ = (1 + θ)/2 and the variance is σ2 = (σ2i + τ
2)/4;
for method 3 the variance is instead σ2 = τ 2/4.
We have the standard result
ψ = α/(α+ β),
σ2 =
αβ
(α+ β)2(α + β + 1)
.
Hence σ2 = ψ(1−ψ)
α+β+1
, so that
α = ψ{ψ(1− ψ)
σ2
− 1},
β = (1− ψ){ψ(1− ψ)
σ2
− 1}.
We must constrain our model parameters so that α and β are positive in
this reparameterisation. This could be a problem if the function minimiser
chooses very large values of σ2 and further reparameterisations could be used
to make the numerical methods more robust.
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7.1 Converting to our new measure
As explained at the end of section 4, we anticipate that some applied ana-
lysts may not be convinced by the case for using our measure in statistical
analysis, but despite this will find the new measure to be an attractive option
for communicating their findings to those with little or no formal statistical
training. To use our proposed measure to communicate findings when al-
ternative measures of treatment effect have been used in analysis, we need
ways to convert other measures to ours. In this section we explain how to
convert the odds ratio to the GRRR. The methods and issues are similar
when converting other measures of treatment effect.
When converting from one measure of treatment effect to another, for
example the odds ratio to the risk difference, we need to take a representative
baseline risk p. This can be the average value of p for the studies in the meta-
analysis, either unweighted or weighted. We can then use the implied q from
one measure of treatment effect to compute the other measure that we wish
to convert to. By taking into account the uncertainty in the first of these
measures, we can communicate the uncertainty in the conversion.
Let us start by converting the odds ratio to a finite range. This can be
done in several ways, the simplest arguably being
φ =
OR− 1
OR+ 1
=
q − p
p+ q − 2pq . (14)
The measure in (14), which itself is easily derived from the definition of the
odds ratio, can then be converted into θ defined by equation (2) of the main
paper. On eliminating q,
θ =
{
2(1−p)φ
1−φ+2pφ
if φ < 0
2pφ
1−φ+2pφ
if φ ≥ 0. (15)
so that the OR can easily be converted to φ, which can then be converted to
our measure θ.
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